AYTU Q3 2026: Exua Prescriptions Jump 51% as Launch Accelerates Beyond Core Markets
Exua’s early launch momentum is reshaping AYTU’s growth profile, offsetting legacy portfolio declines and signaling a durable CNS pivot. Physician adoption is rapidly expanding, with refill rates and payer access exceeding initial expectations, even as only a fraction of the target prescriber base is engaged. Investors should watch for how this disciplined, targeted commercial strategy translates into sustainable revenue and margin gains as Exua scales.
Summary
- Exua Launch Outpaces Early Expectations: Prescriber and prescription growth is driving a meaningful shift in AYTU’s business mix.
- Legacy Portfolio Declines Offset by CNS Expansion: ADHD and pediatric segments contract as focus and resources pivot to Exua.
- Commercial Model Demonstrates Leverage: Early success in both covered and “white space” markets highlights scalable launch economics.
Business Overview
AYTU is a specialty pharmaceutical company focused on commercializing novel therapeutics for central nervous system (CNS) and pediatric indications. Revenue is generated through prescription drug sales across three core portfolios: Exua (CNS, specifically major depressive disorder), ADHD therapies, and a legacy pediatric product suite. The company’s business model is transitioning, with Exua positioned as the primary growth driver and legacy portfolios providing cash flow support during this pivot.
Performance Analysis
AYTU’s Q3 2026 results reflect a business in active transformation. Total net revenue declined year-over-year as expected, driven by a deliberate de-emphasis of legacy ADHD and pediatric portfolios, while Exua’s first full quarter as a commercial product delivered $2.4 million in revenue, exceeding internal launch benchmarks. Exua prescriptions rose sharply, with over 1,300 written in Q3 and April volumes up another 26% sequentially, signaling strong early adoption and growing refill activity.
Gross margin compressed to 61% (from 69% YoY), impacted by a one-time inventory write-down related to ADHD product transition, but underlying Exua unit economics remain attractive, with management targeting a 69% gross contribution margin as scale builds. Operating expenses increased, reflecting planned launch investments, but were offset by improved operational efficiencies elsewhere. Adjusted EBITDA turned negative as expected, reflecting the front-loaded nature of launch spend and legacy revenue contraction.
- Prescription Ramp Drives CNS Mix Shift: Exua now represents a meaningful portion of total revenue, with ongoing sequential growth.
- Legacy Brands Decline as Planned: ADHD net revenue fell due to reduced sales effort and generic entry, while pediatric revenue contracted on payer mix and returns.
- Cash Burn Managed Against Launch Milestones: $26.7 million in cash provides runway for continued Exua investment and commercial execution.
Momentum in Exua’s early uptake, breadth of prescribers, and positive payer dynamics are the most important signals for the company’s trajectory as it pivots to CNS leadership.
Executive Commentary
"The most important point here, though, is that physicians are already writing Exua, patients are beginning therapy, and very early refill activity is already becoming evident. In Q3, more than 1,300 prescriptions were written for Exua... Importantly, that momentum has continued. In April, we saw over 920 prescriptions written, up from the 700 in March. That's a 26% month-over-month sequential growth rate."
Josh Disbrow, Chief Executive Officer
"Exua net revenue of $2.4 million in the quarter was a strong initial result and ahead of our internal expectations... The first few months of any launch include noise, and that is especially true for a product like Exua, where our strategy is intentionally designed to remove early access barriers for patients and prescribers."
Ryan Selhorn, Chief Financial Officer
Strategic Positioning
1. Focused CNS Launch Model
AYTU is executing a disciplined, targeted launch for Exua, prioritizing high-value psychiatry prescribers and leveraging the RxConnect platform, RxConnect, patient access platform, to reduce friction for both clinicians and patients. This model is designed to maximize early adoption while controlling costs and avoiding broad, inefficient spend.
2. Access and Payer Strategy
Early reimbursement outcomes have been better than modeled, with over 70% of prior authorizations approved on first pass in the RxConnect network and positive coverage trends in both commercial and government channels. AYTU’s approach of guaranteeing initial access for commercially insured patients is facilitating trial and conversion, with net selling prices currently above initial forecasts.
3. Portfolio Transition and Cash Flow Management
The company is intentionally reallocating resources away from legacy ADHD and pediatric products to fuel Exua’s launch, while still generating cash flow from these portfolios. Generic entry into ADHD has had less impact than feared, with the RxConnect channel proving protective against erosion.
4. Geographic and Prescriber Expansion
Exua adoption is occurring beyond AYTU’s core sales footprint, with prescriptions written in over 40 states, including “white space” markets with no direct rep presence. This organic pull-through signals significant upside as the sales force matures and coverage expands.
5. Commercial Leverage and Launch Durability
AYTU is scaling its commercial team in phases, with only a partial quarter of full sales force activity reflected in Q3 results. Early refill trends and positive patient outcomes indicate durable demand, supporting the thesis that Exua can become an anchor CNS asset with attractive long-term economics.
Key Considerations
This quarter marks a turning point as AYTU’s growth narrative shifts from legacy brands to CNS innovation, with Exua’s launch performance the critical lever for future value creation. The company’s strategy hinges on disciplined commercial execution, payer access, and sustained prescriber adoption.
Key Considerations:
- Early Launch Metrics Signal Product-Market Fit: Prescription growth, refill rates, and prescriber breadth provide tangible evidence of clinical and commercial traction.
- Reimbursement Dynamics Remain Favorable: High initial approval rates and above-budget net selling prices support margin expansion as volume builds.
- Legacy Business Provides Runway: ADHD and pediatric cash flows are supporting Exua investment, with generic impact less severe than anticipated in protected channels.
- Geographic Expansion Opportunity: Uncovered states are generating organic Exua demand, suggesting further upside as sales resources are deployed more broadly.
- Operating Discipline Is Central to Model: Management is aligning launch spend with performance, maintaining flexibility to adapt as Exua scales.
Risks
AYTU’s pivot exposes it to several material risks: launch variability, payer mix shifts, and the possibility of slower-than-expected prescriber adoption as the initial excitement fades. Gross-to-net dynamics and refill rates could pressure revenue as patient support programs mature, while legacy portfolio declines may accelerate if generic competition intensifies or payer dynamics shift. Regulatory or reimbursement headwinds in CNS could also introduce volatility.
Forward Outlook
For Q4 2026, AYTU signaled:
- Increased sales and marketing spend by $1–2 million for digital and peer programs
- G&A expenses expected to rise by $200,000–$300,000 with expanded educational initiatives
For full-year 2026, management did not provide formal guidance but reiterated:
- Gross margins expected in the mid to high 60% range over time
- Path to profitability as Exua revenue builds on the legacy platform
Management highlighted several factors that will shape near-term results:
- Normalization of gross-to-net as payer mix and RxConnect utilization stabilize
- Ongoing expansion of the prescriber base and geographic reach
Takeaways
AYTU’s Q3 marks a successful inflection in its CNS strategy, with Exua’s early uptake validating management’s focused, data-driven launch approach and supporting the case for durable growth as the product scales.
- Exua’s Launch Trajectory Surpasses Initial Benchmarks: Prescription and refill momentum, coupled with positive payer feedback, underpin a robust early growth profile and set the stage for broader adoption.
- Legacy Revenue Declines Are Contained: ADHD and pediatric segments are tracking as expected, providing cash flow to support CNS investment while minimizing downside from generic entry.
- Forward Investors Should Monitor Margin Normalization and Prescriber Expansion: Watch for stabilization in gross-to-net and evidence of durable, repeatable demand as Exua matures beyond the initial launch window.
Conclusion
AYTU’s Q3 results confirm the company’s successful transition toward CNS leadership, with Exua’s launch delivering outsized early returns and validating the disciplined commercial model. The next phase will test AYTU’s ability to sustain this momentum, scale efficiently, and convert early prescriber enthusiasm into lasting revenue growth.
Industry Read-Through
AYTU’s Exua launch offers several signals for specialty pharma and CNS peers: Focused, data-driven commercial models can drive rapid early adoption in targeted prescriber segments without broad field force expansion. Positive payer dynamics and access programs are critical in CNS launches, especially where patient and prescriber friction can impede uptake. Legacy portfolio management remains a key risk mitigant during pipeline-to-commercial transitions, with channel protection strategies (like RxConnect) helping to blunt generic erosion. Other CNS and specialty pharma players should note the importance of real-world evidence and patient outcomes in accelerating prescriber buy-in and payer coverage.